retatrutide safety trial Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Investigating the “efficacy and safety

Abdominal pain is common

Each 4 oz

By boosting NAD+ levels, NAD IV infusions may enhance cellular metabolism and energy production

shows liver size, texture, fat, masses, and signs of portal hypertension CT or MRI: give more detail, and are used to evaluate masses or vascular changes MR cholangiopancreatography (MRCP): looks at the bile ducts in suspected duct diseases Fibrosis assessment Estimating how much scarring is present is central to deciding treatment intensity and monitoring frequency

4.6% in the non-GLP-1 group Significantly lower rates of acute myocardial infarction Lower risk of major adverse cardiac events overall Psoriatic arthritis already raises cardiovascular risk substantially